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Abstract
Objective To investigate patient experience of CTcolonography
(CTC) and colonoscopy in a national screening programme.
Methods Retrospective analysis of patient experience postal
questionnaires. We included screenees from a fecal occult
blood test (FOBt) based screening programme, where CTC
was performed when colonoscopy was incomplete or deemed
unsuitable. We analyzed questionnaire responses concerning
communication of test risks, test-related discomfort and post-
test pain, as well as complications. CTC and colonoscopy
responses were compared using multilevel logistic regression.
Results Of 67,114 subjects identified, 52,805 (79 %)
responded. Understanding of test risks was lower for CTC
(1712/1970 = 86.9 %) than colonoscopy (48783/
50975 = 95.7 %, p < 0.0001). Overall, a slightly greater pro-
portion of screenees found CTC unexpectedly uncomfortable
(506/1970 = 25.7 %) than colonoscopy (10,705/50,975 =
21.0 %, p < 0.0001). CTC was tolerated well as a completion
procedure for failed colonoscopy (unexpected discomfort;
CTC = 26.3 %: colonoscopy = 57.0 %, p < 0.001). Post-
procedural pain was equally common (CTC: 288/1970,
14.6 %, colonoscopy: 7544/50,975,14.8 %; p = 0.55).
Adverse event rates were similar in both groups (CTC: 20/
2947 = 1.2 %; colonoscopy: 683/64,312 = 1.1 %), but gener-
ally less serious with CTC.
Conclusions Even though CTC was reserved for individuals
either unsuitable for or unable to complete colonoscopy, we
found only small differences in test-related discomfort. CTC
was well tolerated as a completion procedure and was ex-
tremely safe. CTC can be delivered across a national screening
programme with high patient satisfaction.
Key Points
• High patient satisfaction at CTC is deliverable across a
national screening programme.
• Patients who cannot tolerate screening colonoscopy are
likely to find CTC acceptable.
• CTC is extremely safe; complications are rare and almost
never serious.
• Patients may require more detailed information regarding
the expected discomfort of CTC.
Keywords Colon cancer . Computed tomography .
Endoscopy . Fecal occult blood test . CTcolonography (CTC)
Introduction
Patient experience is fundamental to high-quality healthcare,
and is important to patients [1] and policy-makers [2].
Although healthcare services are increasingly scrutinized,
many quality assessments overlook patient experience. This
is particularly important for screening programmes, as they
are predicated on high uptake and acceptability. Mass screen-
ing for colorectal cancer (CRC) has been introduced in many
countries [3], most often using fecal occult blood testing
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(FOBt) followed by colonoscopy for those testing positive [4,
5]. This reduces CRC-related mortality, proven by random-
ized trials [6].
In a proportion of individuals, it is not possible to intubate
the entire colon–whether due to frailty, technical difficulty, or
simply refusal. In this situation, one alternative is to offer CT
colonography (CTC), since it is highly sensitive for CRC and
polyps both as a primary screening tool [7, 8] and in FOBt-
positive individuals [9]. Pan-European consensus recom-
mends CTC when colonoscopy is incomplete or not possible
[10–12]. Relatively little is known regarding the relative ac-
ceptability of CTC versus colonoscopy in this setting.
CTC is generally well-tolerated in comparison to colonos-
copy [13–15]. Two randomized studies, one of asymptomatic
screenees [16] and one of symptomatic older patients [17]
reported similar acceptability of CTC and colonoscopy, with
the balance marginally in favour of colonoscopy for screenees
[18] and CTC for symptomatic patients [19]. However, it is
unknown whether these findings are replicated in routine clin-
ical practice beyond randomized trials. Furthermore, the rele-
vance of these findings to FOBt-based programmes, in which
direct colonic investigation is a second-stage test, is also
unknown.
Here we describe patient experience of CTcolonography in
a national FOBt-based CRC screening programme when co-
lonoscopy is not possible or incomplete.
Methods
Ethical permissions
Permission to access anonymized, routinely-coded data was
granted by the English Bowel Cancer Screening Programme.
Approval for evaluation of retrospective, anonymized data
was granted by our institutional research office.
Participants
The English Bowel Cancer Screening Programme (BCSP) is a
national screening programme using biennial FOBt and colo-
noscopy for those testing positive [20]. Eligible residents aged
60-74 years are mailed a FOBt kit, and those testing positive
are invited for a clinical assessment and colonoscopy at a local
hospital Bscreening centre^. CTC is substituted if colonoscopy
is judged inappropriate or infeasible (e.g. due to co-morbidity)
or if colonoscopy is incomplete (e.g. impassable tumour/stric-
ture, technical failure). All patients are assessed by a trained
healthcare professional prior to colonoscopy or CTC, and the
decision to refer to CTC rather than colonoscopy due to un-
suitability for the latter is ratified by a screening-accredited
colonoscopist. All participants undergoing a colonic test are
sent a standard questionnaire 30 days after the process. Here
we present data for screenees tested between January 1st,
2011, and December 31st, 2012, (the first two full calendar
years after programme roll-out) and focus on CTC-related
outcomes; colonoscopy-specific data will be reported
elsewhere.
Procedures
CTC requirements include dual patient positioning, fecal tag-
ging, carbon dioxide insufflation, multislice scanners, trained
staff, and a CTCworkstation. There are no stipulations regard-
ing use or quantity of purgation; recent survey data suggest the
commonest strategy is to use either two sachets of sodium
picosulfa te/magnesium ci t ra te (Picolax, Ferr ing
Pharmaceuticals, West Drayton, UK) or 100-150 mL of sodi-
um diatrizoate/meglumine diatrizoate (Gastrografin, Bayer
plc, Newbury, UK) as a combined purgation/tagging agent.
Use of intravenous contrast is discouraged unless specifically
needed (e.g. for tumour staging). Radiologists must interpret
>100 cases per annum (both screening and symptomatic) be-
fore commencing work for the programme [12]. Sixty percent
of centres perform >300 CTC per year [21]. All programme
colonoscopies are performed by screening-accredited
colonoscopists, a process requiring (a) completion of >1000
colonoscopies, (b) success in a written multiple-choice ques-
tion examination, and (c) successful evaluation of two ob-
served colonoscopies by an external assessor [22].
Sedoanalgesia is administered as required.
Outcome measures
The patient questionnaire addresses the screening invitation,
the pre-colonic test assessment, the preparation for their co-
lonic test, the test itself (including discomfort), post-test symp-
toms, communication of results, and privacy/dignity. Most
items are answered with a five-point Likert-type scale
(Bstrongly agree^ to Bstrongly disagree^) or a binary Byes/
no^ response.
Data recording and extraction
We used the BCSP database to extract: participant age, sex,
date of screening, screening centre used, screening round (i.e.
number of times previously screened via FOBt), colonic test
performed, test result, need for any subsequent tests (e.g. co-
lonoscopy following a positive CTC result), recorded compli-
cations (entered by screening programme staff), and question-
naire results. Socioeconomic deprivation was estimated using
the index of multiple deprivation (IMD) from 2007, a com-
posite deprivation measure linked to postal (ZIP) code.
Complications for CTCwere divided into direct (i.e. attributed
to CTC) and downstream (i.e. after an additional test follow-
ing CTC).
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Data analysis
Data were coded using SPSS v21 for Windows (IBM Corp,
Armonk, NY, USA) and analyzed with R version 3.0.1 for
Mac (R Foundation for Statistical Computing, Austria,
Vienna). Participants not responding to any questionnaire item
were excluded from the patient experience analysis but were
included when calculating complication rates. Missing ques-
tionnaire data for those who responded to at least one ques-
tionnaire item were handled via 10 multiple imputations using
the mice package for R under the missing at random assump-
tion [23]. Variables used in the imputation model were patient
age, sex, socio-economic deprivation, screening round, test
used, screening outcome, and questionnaire results.
Following imputation, questionnaire data with a Likert-
type scale were collapsed into binary categories of Bagree-
ment^ and Bnon-agreement^ because initial analysis showed
the data violated the proportional odds assumption.
Subsequently, multilevel binary logistic regression was used,
with the diagnostic test being performed (i.e. CTC or colonos-
copy) as the explanatory variable. Covariates in the regression
model were the same as those used for the imputation model,
although the occurrence of complications and other question-
naire responses were excluded. The model accounted for clus-
tering of screenees into screening centres. All statistical tests
were conducted on each multiply imputed data set and pooled
according to Rubin [24].
Since we expected that screenees undergoing CTC follow-
ing colonoscopy (i.e. incomplete colonoscopy) and those
triaged directly for CTC (i.e. judged unsuitable for colonos-
copy) may have had differing experience, we compared these
subgroups. Additionally, we expected that those who
underwent colonoscopy following CTC were more likely to
require polypectomy (contingent on a CTC abnormality),
which increases procedural complexity; hence, subgroup anal-
ysis was also performed here.
CTC questionnaire results for individual centres were com-
pared using funnel plots constructed with exact binomial con-
trol limits at 2 and 3 standard deviations [25]. We also used
logistic regression to examine whether centres using non-
laxative preparation for CTC (data taken from reference
[21]) had differences in test discomfort.
Results
Of 67,114 potentially eligible screenees, 52,805 returned a
questionnaire (78.7 % overall; 51,554/65,197 = 79.1 % for
colonoscopy; 2018/2946 = 68.5 % for CTC; Fig. 1). Of these,
603 were excluded due to administrative or data entry errors
(incorrect questionnaire mailed, or questionnaire date before
test date). One hundred and ninety-seven individuals had no
record of undergoing either CTC or colonoscopy. Ultimately,
52,202 questionnaires were analysed, 50,975 for colonoscopy
and 1,970 for CTC (Fig. 1).
Demographics and screening characteristics are summarised
in Table 1. Slightly more respondents (1191/1970 = 60.0 %)
underwent CTC because of contraindications to colonoscopy
rather than incomplete colonoscopy (779/1970, 40.0 %).
Individuals who underwent CTC were older (CTC: mean
66.9 years; colonoscopy: mean 66.3 years, p < 0.0001) and
more likely to be female (CTC: 1017/1970 = 51.6 % female;
Colonoscopy: 21,111/50975 = 41.4 %, p < 0.0001, Table 1).
Average socio-economic deprivation was greater for those
who underwent CTC (median deprivation = 48th percentile)
than colonoscopy (median deprivation = 42nd percentile), with
no difference between the CTC subgroups.
Relatively few responses were missing, ranging from 0.6-
15.6 % for the different questionnaire items. There were no
differences between complete-case analysis and multiply im-
puted analysis for any items; multiply imputed responses are
reported here, with complete-case data shown in Table 2.
Items regarding pre-test experience
Satisfaction with the communication of risks and benefits of
CTC was high. Respondents agreed or strongly agreed they
understood both risks (1712/1970 = 86.9 %) and benefits
(1844/1970 = 93.6 %) of CTC. Understanding was slightly
higher for colonoscopy, with 48,783/50,975 = 95.7 % agreeing
they had understood its risks (odds ratio [OR] = 3.01, 95 %CI
2.59-3.51, p < 0.0001) and 50,057/50,975 = 98.2 % understand-
ing benefits (OR = 3.31, 95 %CI 2.61-4.19, p < 0.0001).
Respondents found bowel preparation instructions clear, for
both CTC (1875/1970 = 95.2 % agreement) and colonoscopy
(49,905/50,975 = 97.9 %), with a small, but statistically signifi-
cant difference in favour of colonoscopy (OR= 1.89, 95 %CI
1.50-2.40, p < 0.0001, Table 2).
Items regarding the test procedure
Approximately one quarter (506/1970 = 25.7 %) of respon-
dents found CTC more uncomfortable than expected. This
was a larger proportion than for colonoscopy (10,705/50,
975 = 21.0 %; OR = 0.81, 95 %CI 0.72-0.91, p < 0.0001).
This difference remained even for patients who denied re-
ceiving sedation during their colonoscopy (Table 3). There
was no significant difference in asking for the test to be
stopped/paused (CTC: 114/1970 = 5.8 %; colonoscopy:
2600/50,975 = 5.1 %, p = 0.28), whether or not patients re-
ported receiving sedation for their colonoscopy (Table 3).
Almost all individuals agreed they had been treated with
both privacy and respect for both tests, although again
there were small, but statistically significant differences
in favour of colonoscopy (Table 2).
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Items regarding the post-test experience
There was no significant difference in the proportion of
respondents who recalled suffering rectal/abdominal pain
following their diagnostic test (CTC: 288/1970,14.6 %,
colonoscopy: 7544/50,975,14.8 %; p = 0.55). Again, there
was no discernable effect of sedation on this questionnaire
item (Table 3). Those who had undergone CTC were less
likely to have received their results within seven days
(1564/1970 = 79.4 %) than for colonoscopy (42,105/50,
975 = 82.6 %; p < 0.0001). A greater proportion of those
who underwent colonoscopy agreed they understood their
resu l ts (49 ,395/50,975 = 96.9 %) than for CTC
(1783/1970 = 90.5 %; OR = 3.26, 95 %CI 2.71-3.91,
p < 0.0001; Table 2).
Variation by indication for CTC
There were few differences between questionnaire results
for the two CTC subgroups (Table 4). Only the assess-
ment of clarity of bowel preparation and signing of in-
formed consent were significantly different, both judged
superior for the group with prior incomplete colonoscopy.
Specifically, unexpected discomfort and post-test
anorectal/abdominal pain were no different between the
two CTC subgroups.
CTC performed when colonoscopy judged unsuitable
Of the 1191 screenees who underwent CTC after being
judged unsuitable for colonoscopy, 161 underwent a sub-
sequent colonoscopy (to investigate CTC-diagnosed ab-
normality). These individuals reported no significant dif-
fe rence in discomfor t be tween the i r CTC (30/
161 = 18.6 % experienced greater than expected discom-
fort) and colonoscopy procedures (32/161 = 19.9 %,
p = 0.89). Similarly, there was no significant difference
in rates of asking for the test to be stopped or paused
(CTC: 6/161 = 3.7 %, colonoscopy: 5/161 = 3.1 %,
p > 0.99) or post-test anorectal/abdominal pain (CTC: 21/
161 = 13.0 %; colonoscopy: 24/161 = 14.3 %, p = 0.75).
CTC performed after incomplete colonoscopy
Screenees who had CTC following colonoscopy (using
CTC as a completion test) completed 779 questionnaires.
A significantly greater proportion of this subgroup found
colonoscopy more uncomfortable than expected when
compared with CTC (CTC: 205/779, 26.3 %; colonosco-
py: 444/779, 57.0 %, p < 0.001). Similarly, these individ-
uals reported more anorectal/abdominal pain after colo-
noscopy (187/779, 24.0 %) than after CTC (108/779,
13.9 %, p < 0.001, Fig. 2).
Fig. 1 Study flowchart of inclusions and exclusions (also see text). The
term Bother test^ refers to flexible sigmoidoscopy, barium enema, and
non-colonographic abdominopelvic CT scanning, all of which were
occasionally used in the programme during the study period (the latter
two tests have since been removed as testing options)
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Variation across screening centres
There was moderate variation between different centres re-
garding the proportion of screenees reporting more than ex-
pected pain (median centre = 25.0 %, IQR = 20.0-31.8 %),
anorectal or abdominal pain after the procedure (median =
13.8 %, IQR = 7.8-19.2 %), and requirement for the test to
be stopped or paused (median = 5.0 %, IQR = 2.6-9.7 %).
However, numbers of responses from individual centres were
small, meaning that these variations largely remained within
control limits (see funnel plots, Fig. 3). After adjustment for
covariates, centres using reduced-laxative bowel preparation
had no differences in greater than expected levels of test dis-
comfort, post-test pain, requirement for the test to be stopped/
paused or perceived clarity of the bowel preparation
instructions.
Post-procedural complications
Data regarding complications were available for 2947 individ-
uals (2988 CTC examinations). Fifteen screenees had compli-
cations recorded, which were attributed to CTC (nine severe
pain, five adverse reactions to bowel preparation or intrave-
nous medication, and one venous thromboembolism), giving
a per-test and per-screenee complication rate of 0.5 %. An
additional 20 screenees experienced complications (15 severe
pain, five with bleeding) as a result of further tests provoked
by abnormal or incomplete CTC, giving a total complication
rate (including downstream complications) of 1.2 %. No pa-
tient had perforation. A total of 66,783 colonoscopies were
performed in 64,312 individuals, of whom 683 had complica-
tions, corresponding to a per-test rate of 1.0 % and a per-
patient rate of 1.1 %. However, more serious complications
were recorded after colonoscopy, including 34 perforations,
10 cardiac arrhythmias, and two respiratory arrests.
Discussion
Colonoscopy and CTC are the preferred methods of pan-
colonic investigation for screening and symptomatic patients.
Most reports of large-scale implementation have focused on
detection rates and safety [20, 26, 27], but patient experience
is also an important facet. Using self-reported patient ques-
tionnaires, we documented patient experience in a national
FOBt-based CRC screening programme employing CTC in
accordance with international consensus [10, 11]. Overall sat-
isfaction was high for both tests, although CTC was slightly
more likely to be judged unexpectedly uncomfortable than
was colonoscopy. There was no difference in the rate of intol-
erable symptoms requiring either test to be stopped or paused,
or in anorectal/abdominal pain after the procedure.
Complication rates were similar, but less serious after CTC.Ta
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These data show the Breal-world^ acceptability between the
two tests, when employed as per current practice recommen-
dations. It is extremely reassuring that although CTC is spe-
cifically reserved for individuals who are challenging to in-
vestigate (either because colonoscopy is contraindicated or it
has already failed), overall acceptability and safety of the test
is high. Indeed, differences from colonoscopy (which is per-
formed for the majority of patients, most of whom will be
healthy) were small and all <5 %.
At first sight, our findings regarding patient comfort are
somewhat surprising. Screenees were more likely to report
that CTC was unexpectedly uncomfortable than colonoscopy,
although the absolute difference was small (~5 %). This is
surprising, since CTC is generally viewed as the less invasive
procedure. However, the questionnaire does not record opin-
ions regarding absolute test-related discomfort-only relative
discomfort in comparison to expectations. Respondents may
have had an unrealistic impression of CTC, leading to any
level of discomfort being greater than expected. Conversely,
expectations of colonoscopy may have been for substantial
discomfort. A previous randomised trial of CTC versus colo-
noscopy showed that participants expected significantly great-
er burden from colonoscopy than from CTC [18]. We, there-
fore, suspect that expectations of CTC were for minimal dis-
comfort, and even fairly mild symptoms may have breached
this threshold. Additionally, those undergoing colonoscopy
are frequently offered sedoanalgesia, a factor which might
further mitigate any differences in test discomfort, although
we found that unexpected discomfort was more common at
CTC even when compared to the subgroup of individuals who
did not report having sedation for their colonoscopy (Table 3).
This may again be due to expectations; screenees probably
expect unsedated colonoscopy to be uncomfortable, and they
are generally a self-selecting, motivated, and otherwise
healthy cohort [28].
Nonetheless, a similar proportion of screenees requested
that CTC be stopped or paused to colonoscopy (irrespective
of use of sedation), which implies similar levels of absolute
test-related discomfort. One contributing factor might be in-
herent differences between individuals undergoing CTC and
colonoscopy. For example, those undergoing CTC were older
than those having colonoscopy (albeit only by approximately
6 months), and more likely to be female. Furthermore, by
definition CTC was only performed when colonoscopy was
incomplete or deemed unsuitable initially. Such individuals
may be particularly prone to finding any colonic procedure
uncomfortable. It is important to emphasise that this is the
precise manner in which CTC is generally employed in
FOBt-based screening programmes; therefore, our data direct-
ly reflect clinical practice. We were unable to demonstrate an
effect of reduced-laxative preparation on patient comfort, per-
haps because the questionnaire only records comfort during or
after the CTC procedure rather than symptoms from bowel
purgation itself, or underpowering.
Fig. 2 Responses to the question
BThe test was more
uncomfortable than I expected^
for all respondents (top panel) and
those who had undergone CTC
after a previous attempt at
colonoscopy (bottom panel).
Overall, respondents were more
likely to agree that CTCwasmore
uncomfortable than they had
expected, whereas the opposite
was true for those who had
undergone CTC following
colonoscopy
Eur Radiol
Fig. 3 Funnel plots depicting
variation between screening
centres for the three “discomfort-
related” measures of CTC. Each
circle represents the response for
a given screening centre, plotted
against the number of respondents
at that centre, for (a) greater than
expected discomfort, (b) asking
for the test to be stopped or
paused, and (c) rectal or
abdominal pain after the test.
Dashed and dotted lines represent
95 % and 99.9 % control limits,
respectively
Eur Radiol
Importantly, individuals who had colonoscopy prior to
CTC (i.e. failed endoscopy) had high levels of discomfort at
colonoscopy, but tolerated CTC significantly better; indeed, as
well as those in whom CTC was used as a first-line test after
positive FOBt. We hope that this finding will allow clinicians
to reassure screenees who have had a difficult experience at
colonoscopy that they are likely to find CTC tolerable.
CTC generated relatively few direct complications, as
expected for such a safe procedure. While the complica-
tion rate of CTC itself was lower than for colonoscopy,
this difference disappeared once considering downstream
complications due to further tests precipitated by CTC.
However, complications arising after CTC were not seri-
ous: No patient had perforation as a result of CTC (either
directly or downstream), whereas perforation occurred at
a rate of approximately 1 in 1900 following colonoscopy,
comparable with existing literature [26, 29, 30].
Strengths of this study include the large sample size, high
response rate (79 %), and multicenter nature with national
coverage. Although missing data were noted, this was not
problematic. However, our study has limitations. As noted
above, the participants were not randomised, and therefore,
differences may be due to variation between the tested popu-
lations rather than directly reflecting test characteristics.
Arguably, this is unimportant from a clinical perspective:
CTC was employed precisely as is recommended by interna-
tional consensus [10, 11], meaning our results reflect clinical
practice. However, we would strongly caution against using
these data to argue that CTC or colonoscopy is the better-
tolerated test when employed as a primary screening tool for
asymptomatic subjects: CTC was reserved for those who are
unsuitable for colonoscopy (roughly 60:40 split of contraindi-
cations to colonoscopy vs. incomplete colonoscopy) and was
well-tolerated overall, supporting its use in this role. It is im-
possible to know whether or not these potentially vulnerable
individuals would have found colonoscopy more or less tol-
erable than CTC. Our data are likely generalizable to mass
screening programmes based on FOBt/FIT, but will not reflect
the relative patient experience of colonoscopy or CTC when
employed as first-line screening tests.
Although test complications are recorded centrally, we can-
not be certain that all relevant complications were captured
and uploaded successfully. Additionally, due to the large size
of the dataset, most comparisons were highly statistically sig-
nificant, even when absolute differences were small. It is,
therefore, largely a matter of judgement whether or not the
differences we report here are clinically meaningful or not.
In summary, both CTC and colonoscopy have high levels
of satisfaction when used to investigate a positive FOBt result
in a national CRC screening programme. Although screenees
directed to CTC are a different population to those having
colonoscopy, overall test tolerability was good, with only a
small increase in test discomfort and no difference in post-
procedural pain or complication rates. Screenees requiring
CTC after incomplete colonoscopy tolerated CTC extremely
well. Individuals requiring CTC may require more detailed
information regarding expected procedural discomfort.
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